Products
Pegvisomant is commercially available as a powder and solvent for the preparation of a solution for injection (Somavert). It has been approved in many countries since 2005.
Structure and properties
Pegvisomant is a derivative of human growth hormone produced by biotechnological methods. It consists of 191 amino acids and is pegylated at several sites. The amino acid sequence differs from that of the natural hormone. Pegylation prolongs the half-life of the polypeptide.
Effects
Pegvisomant (ATC H01AX01) is an antagonist at the growth hormone receptor. Thus, it blocks signal transduction and reduces the effects of STH in the organism.
Indications
As a second-line agent for the treatment of acromegaly.
Dosage
According to the SmPC. The drug is administered subcutaneously.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Drug-drug interactions have been described with insulins, antidiabetics, and opioids.
Adverse effects
The most common possible adverse effects include injection site reactions, sweating, headache, weakness, infection, nausea, and diarrhea.